Title : NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.

Pub. Date : 2020 Aug 15

PMID : 32586982






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Here we report inhibition of growth and downstream RAS-MAPK signaling in neuroblastoma cells in response to treatment with the SHP2 inhibitors SHP099, II-B08, and RMC-4550. RMC-4550 protein tyrosine phosphatase non-receptor type 11 Homo sapiens